Khairi M. S. Fahelelbom, Moawia M. M. Al-Tabakha, Nermin A. M. Eissa, Dana Emad Eddin Obaid, Sadik Sayed
Khairi M. S. Fahelelbom1*, Moawia M. M. Al-Tabakha2, Nermin A. M. Eissa1, Dana Emad Eddin Obaid1, Sadik Sayed1
1Department of Pharmaceutical Sciences, College of Pharmacy, Al Ain University of Science and Technology, P.O. Box 64141 Al Ain, UAE.
2Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Ajman University, P.O. Box 346 Ajman, UAE.
Volume - 13,
Issue - 6,
Year - 2020
Objective: The aim of this study is to develop and optimize a new an RP-HPLC method for the analysis of lisinopril from pure samples, full and split tablet dosage forms by investigating all relevant factors in order to obtain a simple, reproducible and sensitive technique for the quantitative determination of lisinopril. Method: A number of chromatographic factors have been tested such as the mobile phase composition, retention rate, column temperature and the effect of excipients using C18 column as the stationary phase for the determination of lisinopril. While the tested mobile phase was a mixture of methanol, acetonitrile and phosphate buffer solution. Results: The retention time of lisinopril was found to be 2.6 min at the flow rate of 1.0 ml/min. Excellent linearity was found for the drug concentrations in the range 40-200 µg/mL (r2= 0.9993). The small RSD value (< 4%) obtained indicate that the method is quite precise. The high percentage of recovery was 100.174% (range: 98.7 to 102.4%) which complies with all of pharmacopeias with SD of 1.1. The absence of additional peaks in the chromatogram indicates non-interference of the commonly used excipients in the tablets and hence the method is specific. The small values of LOD (0.210) and LOQ (0.636 µg/mL) obtained by this method indicate the sensitivity of the method. Conclusion: The proposed RP-HPLC method is rapid, sensitive, precise and accurate for the determination of lisinopril. It can be reliably adopted for routine quality control analysis of lisinopril bulk and in its full and splitted tablet dosage forms.
Cite this article:
Khairi M. S. Fahelelbom, Moawia M. M. Al-Tabakha, Nermin A. M. Eissa, Dana Emad Eddin Obaid, Sadik Sayed. Development and Validation of an RP-HPLC Analytical Method for Determination of Lisinopril in Full and Split Tablets. Research J. Pharm. and Tech 2020; 13(6):2647-2652. doi: 10.5958/0974-360X.2020.00470.9
1. Patchett A, Harris E, Tristram E, Wyvratt M, Wu M, Taub D, Peterson D E, Ikeler T, Broeke ten J, Payne L , Ondeyka D, Thorsett E, Greenlee W, Lohr N, Hoffsommer R, Joshua H, Ruyle W, Rothrock J, Aster S, Maycock A, Robinson F, Hirschmann R, Sweet C, Ulm E, Gross D, Vassil T, Stone. C. A new class of angiotensin-converting enzyme inhibitors. Nature, 1980, 288: 280–283
2. The Merck Index, 23rd ed. 2008. Whitehouse Station, New Jersey, 516, 6235.
3. Preetham N.D, Sujana K, Sankar SDP. Development and validation of UV spectrophotometric method for the estimation of lisinopril in bulk and pharmaceutical formulation. Int. J. Pharm. Sci. Rev. Res, 2014, 25: 257–259.
4. Rahman N, Anwar N, Kashif M, Application of pi-acceptors to the spectrophotometric determination of lisinopril in commercial dosage forms. Farmaco, 2005, 60: 605-611.
5. Shraitah M, Okdeh MMS. New Method for Spectrophotometric Determination of Lisinopril in Pure Form and in Pharmaceutical Formulations, Mod. Chem. Appl, 2016, 4: 2-4.
6. Constantinos K. Zacharis, Paraskevas D. Tzanavaras, Demetrius G. Themelis, Georgios A. Theodoridis, Anastasios Economou, Pantelis G. Rigas, Rapid spectrofluorometric determination of lisinopril in pharmaceutical tablets using sequential injection analysis. Analytical and Bioanalytical Chem, 2004, 379: 759–763.
7. Aktas SE, Ersoy L, Sagirli O, A new spectrofluorometric method for the determination of lisinopril in tablets. II Farmaco, 2003, 58:165–168.
8. Beasley CA, Shaw J, Zhao Z, Reed RA. Development and validation of a stability indicating HPLC method for determination of lisinopril, lisinopril degradation product and parabens in the lisinopril extemporaneous formulation. J. Pharm. Biomed. Anal, 2005, 37: 559–567.
9. Adam E, Barakat I, Saeed A. Development and validation of a high performance liquid chromatography method for the determination of lisinopril dihydrate, Asian J. Pharm. Biol. Res, 2012. 2: 94–99.
10. Maslarska V, Tencheva J, Development of analytical method for determination of lisinopril tablets using RP-HPLC method, Int. J. Pharm. Bio. Sci, 2013, 4:163–167.
11. Raju V B., Rao A L, Development, estimation and validation of lisinopril in bulk and its pharmaceutical formulation by HPLC method. E-J. Chem, 2012, 9: 340–344.
12. Kazakevich Y, Lobrutto R, 2007. HPLC for Pharmaceutical Scientists, John Wiley & Sons, New Jersey, USA.
13. Bouabdallah S, Trabelsi H, Bouzouita K, Sabbah S, Reversed-phase liquid chromatography of lisinopril con-formers, J. Biochem. Biophys. Methods, 2002, 54: 391–405.
14. Alquadeib BT, Development and validation of a new HPLC analytical method for the determination of diclofenac in tablets. Saudi Pharm. J. 2019, 27: 66–70
15. Rezaeia M, Ramazani A, Rouhanic M, An Applicable Method for the Estimation of Tetrabenazine by Simple RP-HPLC in Tablet Dosage Form . Chem. Meth. 2017, 1: 136-144
16. Kuna AK, Ganapaty S, Radha GV. A novel RP- HPLC method development and forced degradation studies for semaglutide in active pharmaceutical ingredients and pharmaceutical dosage forms. Int. J. Res. Pharm. Sci., 2019,10(2): 865-873
17. Gedawy A, Al-Salami H, Dass. CR. Development and validation of a new analytical HPLC method for simultaneous determination of the antidiabetic drugs, metformin and gliclazide. J of Food and Drug Analysis, 2019, 27( 1): 315-322
18. Mastanamma SK, Chandini SK, Reehana SK, Saidulu P. Development and validation of stability indicating RP-HPLC method for the simultaneous estimation of Sofosbuvir and Ledipasvir in bulk and their combined dosage form. Future J of Pharm, Sci, 2018, 4(2): 116-123
19. Ph. Eur.2017, 9.0th edition, Strasbourg: Council of Europe,
20. British Pharmacopoeia; 2013. Her Majesty’s Stationery Office: London, UK.
21. United States Pharmacopeial Convention (USP), 2013. USP 36-NF 31; United States Pharmacopeial Convention: Rockville, MD, USA.
22. Stoimenova TB, Piponski M, Serafimovska GT, Stefova M, Development and Validation of a Fast, Simple, Cost-Effective and Robust HPLC Method for Lisinopril Determination in Solid Pharmaceutical Dosage Forms. Macedonian Journal of Chemistry and Chemical Engineering, 2017, 36: 201–209.
23. Fahelelbom KMS, Al-Tabakha MM, Eissa NAM, Javadi J, Evaluation of Certain Pharmaceutical Quality Attributes of Lisinopril Split Tablets. Sci. Pharm, 2016: 84: 646–653.
24. Remko M, Acidity, Lipophilicity, Solubility, Absorption, and Polar Surface Area of Some ACE Inhibitors, Chem. Pap, 2007, 61: 133—141.
25. Technical overview, Control pH during Method Development for Better Chromatography, 2015. Agilent Technologies Inc., USA.
26. Abu Dayyih W, Al Said S. Development and validation of simultaneous estimation of some prills in drug forms. Int. J Pharm. Sci, 2013, 5: 203-213.
27. International Conference on Harmonization (ICH) of technical requirements for registration of pharmaceuticals for human use, 2005, Validation of analytical procedures: Text and methodology Q2 (R1), ICH, Geneva, Switzer-land.